Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A quarter of study participants accounted for three-quarters of newly diagnosed cases of chlamydia, gonorrhea and syphilis.
In the form of direct quotes from the participants
“And So It Happened” profiles people taking HIV treatment and PrEP.
At this year’s AIDSWatch, activists called out CDC director Robert Redfield for the health agency’s patent rights on Truvada for PrEP.
Truvada and Descovy are both highly effective and generally safe options for HIV prevention.
A photo journal of the #PrEP4All activists at the House hearings on Gilead, PrEP, and Truvada pricing.
Gilead Sciences CEO defends high drug prices and claims the CDC does not own the patent to HIV prevention pill Truvada.
Do not fall for Gilead’s vile marketing ploy.
The Truvada manufacturer’s agreement with the Trump Administration is “a tremendous step toward ending the epidemic.”
This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.
Researchers surveyed PrEP-prescribing physicians in Western New York.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
New HIV cases in the city remain higher than those in Los Angeles County and the state.
Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.
An HIV-negative gay man confronts his history with men living with the virus.
An HIV activist responds to an open letter to the CDC director over advocacy on PrEP patents.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.